Last mentioned: Mar 6, 2026
Phase I Milestone
First human subject enrolled and dosed in the Phase I clinical trial.
Phase I Initiation
First human subject enrolled and dosed in the Phase I clinical trial.
AI Discovery
Insilico Medicine identifies ISM4808 using its Pharma.AI platform.
Out-Licensing
TaiGen Biotechnology secures rights for the clinical development of the candidate.
Out-Licensing Deal
TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.
Candidate Discovery
Insilico Medicine identifies ISM4808 using generative AI models.
Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.